The smarter E Europe: Smart Integration Saves Cash and Stabilizes Grids

12.2.2025 18:52:00 EET | Business Wire | Press release

‘Accelerating Integrated Energy Solutions’ - this is the motto of The smarter E Europe 2025, which will take place this year from 7 to 9 May at Messe München.Smart integration is crucial in the evolving energy and mobility sectors. Energy management systems (EMS) for prosumers and businesses have shifted from a nice-to-have to a must-have, making them a key topic at this year’s event.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250212149082/en/

At The smarter E Europe 2025, visitors will find everything for the smart interaction of PV, storage, e-mobility and energy management. (Photo: Solar Promotion GmbH)

GridX, a smart energy company, estimates that the European Home Energy Management System (HEMS) market will expand 11-fold by 2030 across Denmark, Germany, the UK, Italy, the Netherlands, Austria, Sweden, and Spain. This rapid growth reflects increasing demand and evolving regulations.

Regulatory and market requirements

Regulations such as Section 14a of Germany’s Energy Industry Act (EnWG) allow grid operators to control the power output of heat pumps, EV chargers, and battery storage systems. A robust EMS can optimize energy use, reducing reliance on the grid without compromising user comfort.

The challenge of interoperability

Interoperability remains a challenge, with ongoing discussions about standardization. Manufacturer-independent solutions allow greater flexibility for customers. At The smarter E Europe, top industry leaders will address interoperability concerns, emphasizing open standards. In 2018, the OpenEMS Association took a leading role in supporting efforts to create open and manufacturer-independent standards for energy management systems. OpenEMS is not a communication protocol, such as EEBus, but a software platform. The Association counts universities and research institutes, grid operators and industry associations as well as energy management companies among its members.

Focus event hosted by pv magazine and The smarter E Forum

Home energy management is also going to be discussed at the focus event hosted by pv magazine on the second exhibition day, May 8, 2025. Two interactive sessions will shed light on key aspects of quality photovoltaics and storage projects in the small and utility-scale sectors. pv magazine invites interested visitors to ICM – International Congress Center Messe München, room 13, from 1:00pm–5:00pm. It will be held in German. A separate, English-speaking session aimed at an international expert audience will focus on optimizing large-scale storage systems and the quality assurance of planning, design and marketing. Click here to register for the event.

The smarter E Forum will be organizing a dedicated session for prosumer home energy management systems. On Friday, May 9, the key role of HEMS for modern energy management and grid stability will be discussed starting from 1:30pm.

Munich becomes the center of the energy world

In May, at Messe München, innovation will meet practice, and visions will meet concrete solutions. The smarter E Europe shows how the sectors electricity, heat and transportation can be intelligently connected to create a decentralized, digitalized and flexible energy world. From May 7–9, 2025, Messe München is fully booked – the organizers expect more than 3,000 exhibitors and over 110,000 visitors at the exhibition ground covering 206,000 square meters across 19 exhibition halls and the Outdoor Area.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250212149082/en/

Contacts

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release

The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of

Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release

Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated

L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release

L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom